Phase
Condition
Pancreatic Cancer
Pancreatic Disorders
Adenocarcinoma
Treatment
combination therapy with no MEKi
combination therapy with MEKi.
combination therapy with MEKi-HCQ
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥18 years.
Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treatingphysician or tumor board.
Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician.
Ability to understand a written informed consent document and the willingness tosign it.
Exclusion
Exclusion Criteria:
Age <18 years.
Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma
Tumor does not have a KRAS G12R mutation.
Study Design
Study Description
Connect with a study center
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin 53226
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.